Influence of Season on Efficacy and Tolerability of Tazarotene 0.045% Lotion for the Treatment of Acne
Copyright © 2023. Matrix Medical Communications. All rights reserved..
Objective: The condition of the skin can vary due to weather fluctuations. Therefore, this post-hoc analysis evaluated efficacy and safety of tazarotene 0.045% lotion in warmer versus colder months.
Methods: In two Phase III, double-blind, 12-week studies, participants aged nine years or older with moderate-to-severe acne were randomized 1:1 to once-daily tazarotene or vehicle lotion. The pooled population (N=1,614) was stratified by randomization date (warmer=May to September; colder=October to April). Evaluations included inflammatory/noninflammatory lesion counts, treatment success, adverse events, and safety/tolerability.
Results: Tazarotene 0.045% lotion was similarly efficacious over colder and warmer months. Compared with vehicle, tazarotene demonstrated significantly greater least-squares mean absolute reductions from baseline to Week 12 in inflammatory (colder/warmer tazarotene vs. vehicle: -16.6/-15.8 vs. -13.2/-12.9) and noninflammatory lesions (-23.2/-22.6 vs. -17.5/-15.1); treatment success rates were also significantly higher (30.1/30.8% vs. 18.2/17.6%) (P<0.001, all). No strong seasonal trends in safety were observed, though tazarotene led to slightly more discontinuations (3.4% vs. 1.9%) and related adverse events (12.0% vs. 10.3%) in colder versus warmer months. Transient increases in scaling, erythema, and itching at Weeks 2 to 8 of tazarotene treatment were slightly higher in colder versus warmer months but returned to baseline/improved by Week 12.
Limitations: Geographical variation across study sites can lead to varying temperatures and humidity within the same months.
Conclusion: Tazarotene 0.045% lotion was efficacious and well tolerated for acne treatment, regardless of season. Year-round tolerability of tazarotene 0.045% lotion may be due to its lower tazarotene concentration and polymeric emulsion technology, which simultaneously delivers moisturizers/humectants/emollients to skin.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
The Journal of clinical and aesthetic dermatology - 16(2023), 9 vom: 20. Sept., Seite 42-45 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tan, Jerry [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 20.09.2023 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM362170711 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362170711 | ||
| 003 | DE-627 | ||
| 005 | 20231226090702.0 | ||
| 007 | tu | ||
| 008 | 231226s2023 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362170711 | ||
| 035 | |a (NLM)37720201 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tan, Jerry |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Influence of Season on Efficacy and Tolerability of Tazarotene 0.045% Lotion for the Treatment of Acne |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Revised 20.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023. Matrix Medical Communications. All rights reserved. | ||
| 520 | |a Objective: The condition of the skin can vary due to weather fluctuations. Therefore, this post-hoc analysis evaluated efficacy and safety of tazarotene 0.045% lotion in warmer versus colder months | ||
| 520 | |a Methods: In two Phase III, double-blind, 12-week studies, participants aged nine years or older with moderate-to-severe acne were randomized 1:1 to once-daily tazarotene or vehicle lotion. The pooled population (N=1,614) was stratified by randomization date (warmer=May to September; colder=October to April). Evaluations included inflammatory/noninflammatory lesion counts, treatment success, adverse events, and safety/tolerability | ||
| 520 | |a Results: Tazarotene 0.045% lotion was similarly efficacious over colder and warmer months. Compared with vehicle, tazarotene demonstrated significantly greater least-squares mean absolute reductions from baseline to Week 12 in inflammatory (colder/warmer tazarotene vs. vehicle: -16.6/-15.8 vs. -13.2/-12.9) and noninflammatory lesions (-23.2/-22.6 vs. -17.5/-15.1); treatment success rates were also significantly higher (30.1/30.8% vs. 18.2/17.6%) (P<0.001, all). No strong seasonal trends in safety were observed, though tazarotene led to slightly more discontinuations (3.4% vs. 1.9%) and related adverse events (12.0% vs. 10.3%) in colder versus warmer months. Transient increases in scaling, erythema, and itching at Weeks 2 to 8 of tazarotene treatment were slightly higher in colder versus warmer months but returned to baseline/improved by Week 12 | ||
| 520 | |a Limitations: Geographical variation across study sites can lead to varying temperatures and humidity within the same months | ||
| 520 | |a Conclusion: Tazarotene 0.045% lotion was efficacious and well tolerated for acne treatment, regardless of season. Year-round tolerability of tazarotene 0.045% lotion may be due to its lower tazarotene concentration and polymeric emulsion technology, which simultaneously delivers moisturizers/humectants/emollients to skin | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Retinoid | |
| 650 | 4 | |a acne | |
| 650 | 4 | |a season | |
| 650 | 4 | |a tolerability | |
| 650 | 4 | |a weather | |
| 700 | 1 | |a Draelos, Zoe D |e verfasserin |4 aut | |
| 700 | 1 | |a Gooderham, Melinda J |e verfasserin |4 aut | |
| 700 | 1 | |a Alexis, Andrew F |e verfasserin |4 aut | |
| 700 | 1 | |a Graber, Emmy |e verfasserin |4 aut | |
| 700 | 1 | |a Keri, Jonette |e verfasserin |4 aut | |
| 700 | 1 | |a Woolery-Lloyd, Heather C |e verfasserin |4 aut | |
| 700 | 1 | |a Harper, Julie C |e verfasserin |4 aut | |
| 700 | 1 | |a Cook-Bolden, Fran E |e verfasserin |4 aut | |
| 700 | 1 | |a Konda, Adarsh |e verfasserin |4 aut | |
| 700 | 1 | |a Tanghetti, Emil A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of clinical and aesthetic dermatology |d 2008 |g 16(2023), 9 vom: 20. Sept., Seite 42-45 |w (DE-627)NLM200457071 |x 1941-2789 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g number:9 |g day:20 |g month:09 |g pages:42-45 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |e 9 |b 20 |c 09 |h 42-45 | ||